Babler Martin
SEC-identified person · CIK 1435618 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Maplight Therapeutics, Inc. MPLT | Director | filed 2026–2026 |
| Prelude Therapeutics Inc PRLD | Director | filed 2021–2026 |
| Alumis INC. NASDAQ | Director · President, CEO and Chairman | filed 2024–2026 |
| 89bio, Inc. ETNB | Director | filed 2024–2025 |
| Neurogene Inc. NLTX | Director | filed 2020–2023 |
| Omega Alpha Spac OMEG | Director | filed 2021–2021 |
| Principia Biopharma Inc. PRNB | Director · President, CEO | filed 2018–2020 |
| ZS Pharma, Inc. ZSPH | Director | filed 2015–2015 |
| Infinity Pharmaceuticals, INC. INFI | Director | filed 2008–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.